Invion Limited
IVIXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.09M
Close$
$-0.02
141.7% downside
Current Fair Value
141.7% downsideOvervalued by 141.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.09 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.04 |
| Beta | 0.4 |
| Outstanding Shares | 99,085,914 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.59 |
|---|---|
| PEG | 0.84 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Invion Limited
4 employees
CEO: Thian Chew
Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions ...